Maxim upgraded Adial Pharmaceuticals (ADIL) to Buy from Hold with a $1.50 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals Advances AD04 with FDA Support
- Adial announces receipt of final meeting minuts from EOP2 meeting with FDA
- Adial Pharmaceuticals Granted Nasdaq Compliance Extension
- Adial granted a 180 calendar day extension by Nasdaq to regain compliance
- Adial encouraged by U.S. Senate support for extended AUD trial endpoints